Metoprolol vs Carvedilol

In heart failure with reduced ejection fraction (HFrEF), both medications have demonstrated mortality reduction in landmark trials. Carvedilol reduced all-cause mortality by 35% in the COPERNICUS trial ^[2], while metoprolol succinate reduced mortality by 34% in the MERIT-HF trial ^[1]. The COMET trial directly compared carvedilol to metoprolol tartrate (not succinate) and found carvedilol superior, with a 17% relative reduction in all-cause mortality ^[3]. However, many experts note that COMET used metoprolol tartrate at a dose considered suboptimal, and the result may not apply to metoprolol succinate. For hypertension without heart failure, both effectively lower blood pressure. Carvedilol's alpha-blocking activity provides additional peripheral vasodilation, which may offer advantages in patients with peripheral vascular disease ^[4]. For rate control in atrial fibrillation, both are effective, though metoprolol is more commonly used given its availability in IV formulation for acute settings.

Metoprolol's beta-1 selectivity gives it advantages in certain populations. It is less likely to cause bronchospasm, making it safer for patients with reactive airway disease at lower doses ^[1]. Common side effects of both include fatigue (10–15%), dizziness (5–10%), and bradycardia. Carvedilol more commonly causes orthostatic hypotension due to its alpha-blocking effect, reported in 5–10% of patients ^[2]. Carvedilol has metabolic advantages: it has a neutral effect on blood glucose and lipids, while metoprolol may worsen insulin resistance and raise triglycerides ^[3]. Both can cause weight gain (1–2 kg), cold extremities, and sexual dysfunction, though these effects may be less pronounced with carvedilol due to its vasodilatory properties ^[4]. Neither should be abruptly discontinued due to risk of rebound tachycardia and hypertension.

Both medications are available as generics at affordable prices. Generic metoprolol succinate ER 50 mg (30 tablets) costs approximately $4–15, and metoprolol tartrate is even less expensive at $4–8 ^[1]. Generic carvedilol 25 mg (60 tablets for twice-daily dosing) costs $4–15. Brand-name Toprol-XL costs $150–250/month, while brand Coreg costs $200–300/month. The extended-release formulation of carvedilol (Coreg CR) remains more expensive, at $100–200/month generic. Most insurance plans cover both medications at the lowest copay tier.

Dosing convenience differs meaningfully between these two drugs. Metoprolol succinate (extended-release) is taken once daily, which is preferred for adherence ^[1]. Metoprolol tartrate requires twice-daily dosing. Carvedilol immediate-release requires twice-daily dosing with food (food increases absorption and reduces orthostatic hypotension risk) ^[2]. Carvedilol CR (extended-release capsules) offers once-daily dosing but at higher cost. For heart failure titration, both require gradual up-titration over weeks. Metoprolol succinate doses range from 25–200 mg once daily, while carvedilol ranges from 3.125–25 mg twice daily (or 10–80 mg once daily for CR) ^[3]. Neither requires renal dose adjustment.

Carvedilol may be preferred for patients with heart failure (especially based on COMET trial data), diabetes or metabolic syndrome (neutral metabolic effects), or peripheral vascular disease (alpha-mediated vasodilation) ^[2][3]. Metoprolol succinate may be the better choice for patients who prefer once-daily dosing, have reactive airway disease (better beta-1 selectivity at lower doses), need IV beta-blockade for acute situations, or have orthostatic hypotension concerns ^[1]. Both are guideline-recommended first-line beta-blockers for HFrEF. For simple hypertension without heart failure, the choice often comes down to dosing convenience and tolerability. Consult your healthcare provider to determine which beta-blocker is most appropriate for your condition.